GILEAD SCIENCES INC (GILD) Stock Price, Quote, News and Overview
NASDAQ:GILD - Nasdaq - US3755581036 - Common Stock - Currency: USD
GILD Quote, Performance and Key Statistics
109.11
+2.95 (+2.78%)
The current stock price of GILD is 109.11 USD. In the past month the price increased by 3.41%. In the past year, price increased by 66.12%.
GILD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.35 | 13.96B |
Related stock screener links
About GILD
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404 US
CEO: Daniel P. O'Day
Employees: 17600
Phone: 16505743000
GILEAD SCIENCES INC / GILD FAQ
What is the stock price of GILEAD SCIENCES INC today?
The current stock price of GILD is 109.11 USD. The price increased by 2.78% in the last trading session.
What is the ticker symbol for GILEAD SCIENCES INC stock?
The exchange symbol of GILEAD SCIENCES INC is GILD and it is listed on the Nasdaq exchange.
On which exchange is GILD stock listed?
GILD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GILEAD SCIENCES INC stock?
36 analysts have analysed GILD and the average price target is 117.28 USD. This implies a price increase of 7.49% is expected in the next year compared to the current price of 109.11. Check the GILEAD SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GILEAD SCIENCES INC worth?
GILEAD SCIENCES INC (GILD) has a market capitalization of 135.84B USD. This makes GILD a Large Cap stock.
How many employees does GILEAD SCIENCES INC have?
GILEAD SCIENCES INC (GILD) currently has 17600 employees.
What are the support and resistance levels for GILEAD SCIENCES INC (GILD) stock?
GILEAD SCIENCES INC (GILD) has a support level at 104.07 and a resistance level at 117.41. Check the full technical report for a detailed analysis of GILD support and resistance levels.
Is GILEAD SCIENCES INC (GILD) expected to grow?
The Revenue of GILEAD SCIENCES INC (GILD) is expected to grow by 1.08% in the next year. Check the estimates tab for more information on the GILD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GILEAD SCIENCES INC (GILD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GILD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GILD, evaluating the profitability, health, valuation and growth aspects
- GILEAD SCIENCES INC (GILD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GILEAD SCIENCES INC (GILD) Sales and EPS estimates to see what analysts future expectations are.
- GILEAD SCIENCES INC (GILD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GILEAD SCIENCES INC (GILD) Insider and Institutional Ownership to learn about the owners and their transactions.
- GILEAD SCIENCES INC (GILD) Stock Chart to make your own analysis
- GILEAD SCIENCES INC (GILD) Latest news and press-releases to stay up to date.
Does GILEAD SCIENCES INC (GILD) stock pay dividends?
GILEAD SCIENCES INC (GILD) has a dividend yield of 3.15%. The yearly dividend amount is currently 3.14. Check the full fundamental report for a detailed analysis of GILD dividend history, reliability and sustainability.
When does GILEAD SCIENCES INC (GILD) report earnings?
GILEAD SCIENCES INC (GILD) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of GILEAD SCIENCES INC (GILD)?
The PE ratio for GILEAD SCIENCES INC (GILD) is 14.1. This is based on the reported non-GAAP earnings per share of 7.74 and the current share price of 109.11 USD. Check the full fundamental report for a full analysis of the valuation metrics for GILD.
What is the Short Interest ratio of GILEAD SCIENCES INC (GILD) stock?
The outstanding short interest for GILEAD SCIENCES INC (GILD) is 1.9% of its float. Check the ownership tab for more information on the GILD short interest.
GILD Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GILD. When comparing the yearly performance of all stocks, GILD is one of the better performing stocks in the market, outperforming 92.92% of all stocks.
GILD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GILD. GILD scores excellent on profitability, but there are some minor concerns on its financial health.
GILD Financial Highlights
Over the last trailing twelve months GILD reported a non-GAAP Earnings per Share(EPS) of 7.74. The EPS increased by 77.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.76% | ||
| ROA | 10.57% | ||
| ROE | 31.13% | ||
| Debt/Equity | 1.16 |
GILD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to GILD. The Buy consensus is the average rating of analysts ratings from 36 analysts.
For the next year, analysts expect an EPS growth of 76.07% and a revenue growth 1.08% for GILD